Skip to main content

Table 1 Baseline and treatment characteristics

From: Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution

  All patients (n = 198)
Age, median (IQR) 61 (54–66)
Sex  
 Male 163 (82.3%)
 Female 35 (17.7%)
Total pack-years  
 < 10 pack-years 84 (42.0%)
 ≥ 10 pack-years 114 (57.6%)
Alcohol consumption  
 < 20 drinks per week 149 (75.3%)
 ≥ 20 drinks per week 49 (24.7%)
Primary site  
 Tonsil 108 (54.5%)
 Base of tongue 76 (38.4%)
 Soft palate 9 (4.5%)
 Vallecula 3 (1.5%)
 Indeterminate 2 (1.0%)
Clinical T-stage  
 T1 58 (29.3%)
 T2 140 (70.7%)
Clinical N-stage  
 N0 21 (10.6%)
 N1 52 (26.3%)
 N2 125 (63.1%)
p16 status  
 Positive 144 (72.7%)
 Negative 28 (14.1%)
 Unknown 26 (13.1%)
Treatment  
 RT 39 (19.7%)
 CRT 159 (80.3%)
Radiation laterality  
 Unilateral 14 (7.1%)
 Bilateral 163 (82.3%)
 Unknown 21 (10.6%)
CT simulation  
 With contrast 85 (42.9%)
 Without contrast 92 (46.5%)
 Unknown 21 (10.6%)
Chemotherapy regimen  
 Cisplatin 135 (68.2%)
  High dose 83 (61.4%)
  Weekly 52 (38.5%)
 Carboplatinum + 5-fluorouracil 14 (7.1%)
 Cetuximab 5 (2.5%)
 Other 5 (2.5%)
  1. Data are presented as number (%) unless otherwise specified
  2. RT radiotherapy only, CRT chemoradiation